PTIX•benzinga•
Protagenic Therapeutics shares are trading lower. The company reported safety data from the single dose portion of its Phase 1 trial involving PT00114.
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 22, 2024 by benzinga